The Biden administration has launched a website allowing people to sign up for free COVID-19 tests to be shipped to their homes. The federal government will officially roll out its planon Wednesday to distribute the 500 million free tests. (CNN)
Sensorion’s hearing loss drug, arazasetron, failed the primary endpoint in its Phase II study. CEO Nawal Ouzren noted that the company is still “looking forward to reviewing the secondary endpoints once these become available.” (Endpoints News)
Some drugmakers and patient advocacy groups are pushing for the Centers for Medicare and Medicaid Services to cover Biogen Alzheimer’s drug Aduhelm for more people. They argued that CMS’ recent decision will lead to less investment in the Alzheimer’s space. (Politico)
Unauthorized distributors sold counterfeit versions of Gilead Sciences’ HIV treatments, worth $250 million, to pharmacies over the course of two years, the company said Tuesday. The distributors sold more than 85,000 bottles of the drugs. (Reuters)
Biotech startup Affini-T Therapeutics is aiming to develop new cancer therapies by targeting the source of cancer cells. The company will use engineered T-cell receptors (TCRs) to attack cancer-causing mutations in genes. (STAT)
